{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":18,"n_cols":5,"rows_kept":18,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910967797203321"]
[null,null,"Autore",null,"Vinšová Jarmila"]
[null,null,"Titolo",null,"Development of new MDR-tuberculosis drugs / / Jarmila Vinšová and Martin Krátký"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Science Publishers/Nova Biomedical, c2010"]
[null,null,"ISBN",null,"1-61668-478-X"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (112 p.)"]
[null,null,"Collana",null,"Pharmacology-research, safety testing and regulation"]
[null,null,"Disciplina",null,"615.5/8"]
[null,null,"Soggetti",null,"Antitubercular agents"]
[{"$nulls":4},"Multidrug-resistant tuberculosis - Chemotherapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Resistance to commonly used drugs, mechanism of the action -- Research of novel MDR potential drugs."]
[null,null,null,"Sommario/riassunto","The emergence of resistance to anti-tuberculosis drugs, particularly of MDR-TB and newly XDR-TB, has become a major public health problem. The current treatment regiment has several disadvantages, i.e. long treatment period (DOTS takes minimum 6 months) during which tubercle bacilli mutant become resistant to one or more drugs; side effects of the used drugs; co-infection of HIV/AIDS. The emergence of MDR-TB has made many currently available anti-TB drugs ineffective. Sleeping latent forms of mutant bacilli resistant against common anti-TB drugs pose the risk of epidemic for the new generation. This book outlines the recent advances in the development of new multi-drug-resistant tuberculosis (MDR-TB) drugs."]